Back to top

Analyst Blog

Wright Medical Group, Inc. (WMGI - Analyst Report) posted a broader loss of $8.2 million or 18 cents per share in the third quarter of the year compared with $1.6 million or 4 cents in the same quarter of 2012. With this, earnings meet the Zacks Consensus Estimate.

Reported net loss was $124.5 million or $2.68 per share, compared with $4.1 million or 11 cents in the third quarter of 2012. Net revenues increased 13.3% (14% in constant currency) to $57.6 million during the quarter, exceeding the Zacks Consensus Estimate of $56.0 million.

Gross profit rose 11.3% to $43.6 million from $39.2 million a year ago but gross margin decreased 200 basis points (bps) to 75.6% from 77% a year ago. Adjusted operating loss significantly increased to $11.5 million from $1.0 million a year ago. Adjusted operating (loss) margin rose to 19.9% from 2.0% a year ago.

WMGI had cash and cash equivalents and marketable securities of $279.2 million as of Sep 30, 2013, down from $333.0 million as of Dec 31, 2012 due to the closing of the BioMimetic transaction and expenses associated with the MicroPort transaction. Long-term obligations rose to $265.0 million from $258.5 million as of Dec 31, 2012.

In the first nine months of the year, cash flow from operations declined significantly to $5.7 million from $57.8 million in the same period a year ago. Capital expenditures increased 69.4% to $22.5 million from $13.3 million a year ago.

Wright Medical narrowed its revenue guidance for 2013 to $237–$240 million from $235–$240 million, which has incorporated short-term dis-synergies due to the previously announced transaction with MicroPort. However, WMGI reiterated its adjusted earnings per share guidance of a loss of 55 to 59 cents, based on approximately 45.3 million shares outstanding.

Arlington, Tenn.-based Wright Medical Group is a global orthopaedic device company specializing in the design, manufacture and marketing of reconstructive joint devices and bio-orthopaedic materials. Currently, WMGI retains a Zacks Rank #3 (Hold).

Other medical stocks that are performing well include Bio-Rad Laboratories, Inc. (BIO - Snapshot Report), Hill-Rom Holdings, Inc. (HRC - Snapshot Report), and INSYS Therapeutics, Inc. (INSY - Snapshot Report). All of them carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%